IV Fluid Composition Table
IV Fluid Composition Table
IV Fluid Composition Table
Content Plasma Sodium Sodium 0.45% 5% Hartmann’s Lactated Ringer’s Alternative Alternative
a
chloride chloride NaCl/ glucose Ringer’s acetate balanced balanced
0.9%* 0.18%/ 4% (USP) solutions for solutions for
4% glucose
a resuscitation** maintenance**
a
glucose
+
Na 135–145 154 31 77 0 131 130 130 140 40
(mmol/l)
–
Cl (mmol/l) 95–105 154 31 77 0 111 109 112 98 40
+ –
[Na ]:[Cl ] 1.28–1.45:1 1:1 1:1 1:1 - 1.18:1 1.19:1 1.16:1 1.43:1 1:1
ratio
+
K (mmol/l) 3.5–5.3 * * * * 5 4 5 5 13
–
HCO3 / 0 0 29 (lactate) 28 27 27 (acetate) 16 (acetate)
Bicarbonate 24–32 0 0 (lactate) (acetate) 23 (gluconate)
2
Ca + 2.2–2.6 0 0 0 2 1.4 1 0 0
(mmol/l) 0
2
Mg + 0.8–1.2 0 0 0 0 1 1.5 1.5
(mmol/l)
Glucose 3.5–5.5 0 222 0 278 0 0 0 0 0
(mmol/ l) (40 g) (50 g)
pH 7.35–7.45 4.5–7.0 4.5 3.5–5.5 5.0–7.0 6–7.5 6–8 4.0–8.0 4.5–7.0
Osmolarity 275–295 308 284 278 278 273 276 295 389
(mOsm/l)
*
These solutions are available with differing quantities of potassium already added, and the potassium-containing versions are usually more appropriate for meeting maintenance needs.
**
Alternative balanced solutions are available commercially under different brand names and composition may vary by preparation.
a
The term dextrose refers to the dextro-rotatory isomer of glucose that can be metabolised and is the only form used in IV fluids. However IV fluid bags are often labelled as glucose so only this term
should be used. Traditionally hospitals bought a small range of fluids combining saline (0.18-0.9%) with glucose but several recent NICE/NPSA documents have recommended specific combinations,
which are now purchased to enable guidelines to be followed. Glucose–saline combinations now come in 5 different concentrations, and the addition of variable potassium content expands the pre-mixed
range to 13 different products. Prescribers must therefore specify the concentration of each component; the term dextrose-saline (or abbreviation D/S) is meaningless without these details. What is specified
also impacts significantly on the cost of the product.
Source: This table was drafted based on the consensus decision of the members of the Guideline Development Group.
‘Intravenous fluid therapy in adults in hospital’, NICE clinical guideline 174 (December 2013)